| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Ogura, Y Furuya, T Teramoto, T Niidome, Y Nishizawa, Y Yamanish. Peptide N- and P/Q-type Ca2+ blockers inhibit stimulant-induced hyperactivity in mice. Peptides. vol 19. issue 6. 1998-10-23. PMID:9700749. |
antagonism of calcium channels, particularly n-type, may ameliorate activation of the dopaminergic system induced by increased dopamine release. |
1998-10-23 |
2023-08-12 |
mouse |
| N V Olse. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans. Danish medical bulletin. vol 45. issue 3. 1998-10-22. PMID:9675540. |
low doses of dopamine predominantly stimulate dopaminergic receptors, but with increasing doses actions secondary to stimulation of adrenergic beta(1) and alpha receptors also appear. |
1998-10-22 |
2023-08-12 |
human |
| K X Huang, D A Bergstrom, D N Ruskin, J R Walter. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra. Synapse (New York, N.Y.). vol 30. issue 1. 1998-10-22. PMID:9704877. |
the present study examined whether n-methyl-d-aspartate (nmda) receptor antagonists affect the neurophysiological responses of substantia nigra pars compacta (snpc; dopaminergic) and pars reticulata (snpr; non-dopaminergic) neurons to a systemically administered d1 dopamine agonist in two animals models of parkinson's disease, reserpine treatment and nigrostriatal lesion. |
1998-10-22 |
2023-08-12 |
rat |
| H C Cromwell, K C Berridge, J Drago, M S Levin. Action sequencing is impaired in D1A-deficient mutant mice. The European journal of neuroscience. vol 10. issue 7. 1998-10-22. PMID:9749770. |
it is known that one of the important influences of dopamine includes sequential co-ordination of 'syntactic' patterns of grooming movements because moderate loss of the dopaminergic nigrostriatal projections specifically disrupts these patterns without affecting grooming actions in a general fashion (berridge, k.c. |
1998-10-22 |
2023-08-12 |
mouse |
| K S McNaught, P A Carrupt, C Altomare, S Cellamare, A Carotti, B Testa, P Jenner, C D Marsde. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochemical pharmacology. vol 56. issue 8. 1998-10-22. PMID:9776302. |
neutral and quaternary isoquinoline derivatives accumulate in dopaminergic nerve terminals via the dopamine re-uptake system, for which they have moderate to poor affinity as substrates. |
1998-10-22 |
2023-08-12 |
human |
| J D Jentsch, A Tran, J R Taylor, R H Rot. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology. vol 138. issue 1. 1998-10-19. PMID:9694531. |
this dopaminergic activation by phencyclidine is not mediated by direct effects on the cell body regions of the dopamine neurons; however, phencyclidine augments dopamine release locally in the terminal fields. |
1998-10-19 |
2023-08-12 |
rat |
| R Takahata, B Moghadda. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. Journal of neurochemistry. vol 71. issue 4. 1998-10-14. PMID:9751176. |
blockade of nmda or ampa receptors in the vta as well as blockade of ampa receptors in the pfc reduced the dopaminergic response to mild handling, suggesting that activation of glutamate neurotransmission also regulates stimulus-induced increase of dopamine release in the pfc. |
1998-10-14 |
2023-08-12 |
rat |
| V Panajotov. The effect of dopaminergic agents on cell-mediated immune response in mice. Physiological research. vol 46. issue 2. 1998-10-13. PMID:9727502. |
the aim of the study was to determine the effect of selective dopaminergic agents [(+/-)-skf-81297 (d1 agonist), r(-)-2,10,11-trihydroxy-n-propyl-noraporphine (d2 agonist), pergolid (d agonist), r(+)-sch-23390 (d1 antagonist), s(-)-eticlopride (d2 antagonist) and cis-(z)-flupenthixol (d antagonist)] on cell-mediated immune response in vivo and in vitro and to verify the presence of dopamine receptors on murine splenocytes. |
1998-10-13 |
2023-08-12 |
mouse |
| V Panajotov. The effect of dopaminergic agents on cell-mediated immune response in mice. Physiological research. vol 46. issue 2. 1998-10-13. PMID:9727502. |
as the binding studies did not confirm the presence of dopamine receptors on splenocytes, the immunosuppressive efficacy of dopaminergic agents does not seem to be mediated via specific dopamine receptors. |
1998-10-13 |
2023-08-12 |
mouse |
| S Chaki, S Okuyama, S Ogawa, K Tomisaw. Regulation of NMDA-induced [3H]dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochemistry international. vol 33. issue 1. 1998-10-09. PMID:9694039. |
these results suggest that sigma1 binding sites selectively interact with the nmda receptor channel complex among ionotropic glutamate receptors, and that sigma1 binding sites may be involved in modulating the release of dopamine in the rat hippocampus by interacting with the nmda receptor on dopaminergic nerve terminal. |
1998-10-09 |
2023-08-12 |
rat |
| B J Hoffman, S R Hansson, E Mezey, M Palkovit. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Frontiers in neuroendocrinology. vol 19. issue 3. 1998-10-08. PMID:9665836. |
in most dopaminergic cells, dopamine transporter mrna completely overlaps with th mrna-positive neurons. |
1998-10-08 |
2023-08-12 |
human |
| N Aguirre, M Barrionuevo, B Lasheras, J Del Rí. The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. The Journal of pharmacology and experimental therapeutics. vol 286. issue 3. 1998-10-08. PMID:9732373. |
these results appear to indicate that the hyperthermia induced by mdma is not sufficient to produce lasting neurotoxic effects on the serotonergic system, at least at pnd21, and support an important role for dopamine in the mechanism of neurotoxicity of mdma, suggesting that an already developed dopaminergic system is necessary for the expression of the serotonergic deficits. |
1998-10-08 |
2023-08-12 |
rat |
| L Pulvirenti, C Balducci, M Piercy, G F Koo. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. The Journal of pharmacology and experimental therapeutics. vol 286. issue 3. 1998-10-08. PMID:9732383. |
terguride is a prototype drug belonging to a recently characterized class of compounds, dopamine partial agonists, which appear to possess a unique pharmacological profile in altering dopamine neurotransmission, where these drugs act as antagonists in conditions of high dopaminergic tone. |
1998-10-08 |
2023-08-12 |
rat |
| C Beyer, H Raa. Nongenomic effects of oestrogen: embryonic mouse midbrain neurones respond with a rapid release of calcium from intracellular stores. The European journal of neuroscience. vol 10. issue 1. 1998-10-08. PMID:9753134. |
oestrogens have been shown to modulate the differentiation and function of embryonic midbrain dopaminergic neurones by stimulating neurite outgrowth, expression of tyrosine hydroxylase mrna, dopamine uptake and release in spite of the fact that dopaminergic cells in the prenatal midbrain do not express the classical oestrogen receptor. |
1998-10-08 |
2023-08-12 |
mouse |
| C W Olanow, P Jenner, D Brook. Dopamine agonists and neuroprotection in Parkinson's disease. Annals of neurology. vol 44. issue 3 Suppl 1. 1998-10-07. PMID:9749590. |
theoretically, such a protective effect might derive from (a) a levodopa sparing effect, (b) stimulation dopamine autoreceptors resulting in decreased dopamine synthesis, release, and turnover, (c) direct anti-oxidant effects, and (d) restoration of dopaminergic tone to the dopamine-denervated brain so as to restore inhibition to the subthalamic nucleus and thereby diminish stn-mediated excitotoxicity. |
1998-10-07 |
2023-08-12 |
Not clear |
| C W Olanow, P Jenner, D Brook. Dopamine agonists and neuroprotection in Parkinson's disease. Annals of neurology. vol 44. issue 3 Suppl 1. 1998-10-07. PMID:9749590. |
preclinical studies have demonstrated that dopamine agonists reduce dopamine formation in comparison to levodopa, protect cultured dopaminergic neurons from a variety of toxins including levodopa, and protect dopaminergic neurons from toxins and age-related degeneration in some rodent models of parkinsonism. |
1998-10-07 |
2023-08-12 |
Not clear |
| M C Rodriguez, J A Obeso, C W Olano. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Annals of neurology. vol 44. issue 3 Suppl 1. 1998-10-07. PMID:9749591. |
we postulate that the dopamine loss that occurs in pd produces augmented stn activity which, in turn, causes further damage to vulnerable dopaminergic neurons, thereby creating a scenario for an increasing cycle of neuronal loss in the snc. |
1998-10-07 |
2023-08-12 |
Not clear |
| T Kondo, H Shimada, K Hatori, Y Sugita, Y Mizun. Talipexole protects dopaminergic neurons from methamphetamine toxicity in C57BL/6N mouse. Neuroscience letters. vol 247. issue 2-3. 1998-10-06. PMID:9655613. |
the effect of protection of dopaminergic neurons by talipexole, a dopamine (da) agonist, is investigated on a methamphetamine (ma)-induced parkinsonism model of mice (c57bl/6n). |
1998-10-06 |
2023-08-12 |
mouse |
| R D Snyder, M B Friedma. Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by manganese and copper. Mutation research. vol 405. issue 1. 1998-10-02. PMID:9729232. |
it is an increasingly popular hypothesis that the continued degeneration of dopaminergic neurons in parkinson's disease (pd) may be the consequence of aberrant oxidation of dopamine and resultant generation of dna reactive species in pd patients receiving levodopa (l-dopa) therapy. |
1998-10-02 |
2023-08-12 |
Not clear |
| R D Snyder, M B Friedma. Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by manganese and copper. Mutation research. vol 405. issue 1. 1998-10-02. PMID:9729232. |
these findings are in support of the hypothesis that aberrant oxidation of dopamine resulting from non-physiological levels of catalytic metals may contribute to the death of dopaminergic neurons and further suggest that oxidation-dependent dna damage may be the basis for this cell death. |
1998-10-02 |
2023-08-12 |
Not clear |